视网膜母细胞瘤综合治疗疗效分析  

Outcomes of Combined Modality Therapy of Retinoblastoma

作　　者：郁想想[1] 陈长征[1] 赵军阳[2] 郑红梅[1] 叶美红[1] 李璐[1] 武犁[1] 

机构地区：[1]武汉大学人民医院眼科,湖北武汉430060 [2]首都医科大学附属北京同仁医院眼科中心,北京100730

出　　处：《武汉大学学报（医学版）》2012年第2期247-250,共4页Medical Journal of Wuhan University

摘　　要：目的:分析视网膜母细胞瘤(Rb)综合治疗疗效。方法:对2007年11月-2011年5月收治的44例(61只眼)Rb患儿采用化疗、激光、冷冻及眼摘相结合的综合治疗,对其疗效进行回顾分析。结果:61只患眼中A期(5只眼),B期(8只眼),保眼率均为100%,D期(20只眼)保眼率为57.9%,E期(28只眼)保眼率为19.4%。44例患儿中,1例双眼E期患儿死亡,其余均存活。保存的26只患眼中除2只E期患眼无光感,其余患眼均有一定的视力。结论:综合治疗可以提高Rb患者的保眼率及生存质量,并有希望保存患儿的有用视力。Objective： To evaluate the effect of combined modality therapy in retinoblastoma（Rb）.Methods： The clinical data of the 44 Rb cases with 61 affected eyes were reviewed.Results： Enucleation and systemic chemotherapy combined with local therapy（include laser and cryotherapy） were adopted.The rate of eye preservation were 100% in both stage A and stage B,57.9% in stage D,and 19.4% in stage E.Conclusion： The combined modality therapy was effective in retinoblastoma,as it increased the total survival rate and improved life quality of children with retinoblastoma,and it is also hopeful to preserve the children＇s useful vision.

关 键 词：视网膜母细胞瘤 生存率 眼摘率 综合治疗 

分 类 号：R774.1[医药卫生—眼科]